FTC orders biggest ever divestiture in Teva Allergan deal

The US Federal Trade Commission (FTC) has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Brussels under scrutiny for IP policy as US flags risks to innovation

1 May 2026 The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.

Americas

From the courtroom: Hikma v Amarin SCOTUS oral arguments

30 April 2026 The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years.

Americas

Blow for Masimo’s fight with Apple as case against US Customs dismissed

29 April 2026 The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.

More features

Brussels under scrutiny for IP policy as US flags risks to innovation

Squire Patton Boggs promotes partner to head Europe IP&T practice

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Report: 85% of in-house counsel want IP service providers to embrace AI

Moderna loses key mRNA patent in European vaccine fight

Boston-based patent expert departs Mintz for major West Coast firm

Blow for Masimo’s fight with Apple as case against US Customs dismissed

Ligand buys biotech in $739m cash deal with litigation sweetener

FTC orders biggest ever divestiture in Teva Allergan deal

More on this story

Editor's picks

Editor's picks

More features